FDA approves Gilead'''s next-generation HIV PrEP pill, Descovy

Gilead now controls the U.S. HIV pre-exposure prophylaxis market with two separate drugs: Truvada and Descovy, a smaller and safer pill.

Gilead Sciences, the drug giant behind the blockbuster HIV prevention pill Truvada, won FDA approval on Thursday to market Descovy a medication already used by those who have HIV as its next-generation prevention drug.

The final approval follows an August vote in favor of Descovy as a pre-exposure prophylaxis medication, or PrEP, by an FDA advisory panel.
================================================
There are some different ways to look at this discovery but it seems to promote indiscriminate, unprotected gay sex, which doesn't seem like a good thing. And these drugs are $$$ expensive.